China Approves Amgen's Tarlatamab (Imdelltra) for Advanced Small Cell Lung Cancer
Shanghai: Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat.
The drug is a targeted immunotherapy for adults in the extensive-stage of hard-to-treat small cell lung cancer that has worsened despite chemotherapy.
The U.S. drugmaker sells tarlatamab in its home market under the name Imdelltra. It is part of Amgen's pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body's immune system can kill the cancer.
Amgen and Hong Kong-listed BeOne did not respond to requests for comment on launch date or pricing for the Chinese market.
Some Wall Street analysts have said tarlatamab could represent an annual sales opportunity for Amgen of more than $2 billion.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.